Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry. T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wei, Xiping, Decker, Julie M., Liu, Hongmei, Zhang, Zee, Arani, Ramin B., Kilby, J. Michael, Saag, Michael S., Wu, Xiaoyun, Shaw, George M., Kappes, John C.
Formato: Artigo
Idioma:en
Publicado em: American Society for Microbiology 2002
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC127242/
https://ncbi.nlm.nih.gov/pubmed/12019106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC127242/
https://ncbi.nlm.nih.gov/pubmed/12019106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002

Registos relacionados